PMID- 36325658
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20221223
IS  - 1365-2710 (Electronic)
IS  - 0269-4727 (Linking)
VI  - 47
IP  - 12
DP  - 2022 Dec
TI  - The correlation between paclitaxel chemotoxicity and the plasma albumin level in 
      cancer patients.
PG  - 2237-2244
LID - 10.1111/jcpt.13798 [doi]
AB  - WHAT IS KNOWN AND OBJECTIVE: The aim of this study was to evaluate the 
      pharmacokinetics of paclitaxel in cancer patients with hypoalbuminemia following 
      paclitaxel-containing chemotherapy and to provide a reference for the prevention 
      of adverse events (AEs) after paclitaxel administration. METHODS: Peripheral 
      blood was collected from cancer patients treated with paclitaxel. The plasma 
      concentration of paclitaxel was determined by ultra-high performance liquid 
      chromatography after 24 +/- 8 h of chemotherapy, and individual paclitaxel time 
      above a threshold concentration of 0.05 mumol/L (T(c>0.05) ) was calculated using 
      the population pharmacokinetic model. Haematological and non-haematological 
      toxicities were monitored after chemotherapy, and the correlation between 
      different chemotherapy toxicities and T(c>0.05) was evaluated using the Prism 
      software. RESULTS AND DISCUSSION: The enrolled patients were divided into the 
      hypoalbuminemia group and normal albumin level group. The mean T(c>0.05) values 
      in the normal albumin level and hypoalbuminemia groups were 36.89 and 24.93 h, 
      respectively (P < 0.001). The risk of myelosuppression was positively correlated 
      with T(c>0.05) . Due to the lower T(c>0.05) , the incidences of immediate AEs 
      such as gastrointestinal reactions and rashes were higher in the hypoalbuminemia 
      group than in the normal albumin level group, and the incidences of delayed AEs 
      such as myelosuppression and neurotoxicity were lower in the hypoalbuminemia 
      group. WHAT IS NEW AND CONCLUSIONS: Plasma albumin level has a conclusive effect 
      on T(c>0.05) , which can predict the potential clinical toxicity of paclitaxel. 
      The study provides a theoretical basis for administration of paclitaxel.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Fan, Weibin
AU  - Fan W
AUID- ORCID: 0000-0002-2831-8358
AD  - Department of Pharmacy, Changxing People's Hospital, Huzhou, China.
AD  - Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, 
      Huzhou, China.
FAU - Yin, Weiming
AU  - Yin W
AD  - Department of Pharmacy, Changxing People's Hospital, Huzhou, China.
AD  - Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, 
      Huzhou, China.
FAU - Zhou, Feng
AU  - Zhou F
AD  - Department of Respiratory, Zhejiang University School of Medicine Second 
      Affiliated Hospital - Changxing Branch, Huzhou, China.
FAU - Wang, Yinhui
AU  - Wang Y
AD  - Department of Pharmacy, Changxing People's Hospital, Huzhou, China.
AD  - Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, 
      Huzhou, China.
FAU - Fan, Jing
AU  - Fan J
AD  - Department of Pharmacy, Changxing People's Hospital, Huzhou, China.
AD  - Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, 
      Huzhou, China.
FAU - Zang, Farong
AU  - Zang F
AD  - Department of Respiratory, Zhejiang University School of Medicine Second 
      Affiliated Hospital - Changxing Branch, Huzhou, China.
FAU - Lin, Bin
AU  - Lin B
AUID- ORCID: 0000-0003-2222-8228
AD  - Department of Pharmacy, Changxing People's Hospital, Huzhou, China.
AD  - Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, 
      Huzhou, China.
LA  - eng
GR  - 2020ZYC-B12/Zhejiang Medical Association/
GR  - YQ20H310006/Zhejiang Natural Fund/
GR  - 2020ZYY53/Zhejiang Pharmaceutical Association/
PT  - Journal Article
DEP - 20221103
PL  - England
TA  - J Clin Pharm Ther
JT  - Journal of clinical pharmacy and therapeutics
JID - 8704308
RN  - P88XT4IS4D (Paclitaxel)
RN  - 0 (Serum Albumin)
SB  - IM
MH  - Humans
MH  - Paclitaxel/adverse effects
MH  - *Hypoalbuminemia/chemically induced/drug therapy
MH  - *Neoplasms/drug therapy
MH  - Serum Albumin
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
OTO - NOTNLM
OT  - Tc>0.05
OT  - clinical toxicity
OT  - hypoalbuminemia
OT  - myelosuppression
OT  - paclitaxel
EDAT- 2022/11/04 06:00
MHDA- 2022/12/24 06:00
CRDT- 2022/11/03 03:13
PHST- 2022/09/08 00:00 [revised]
PHST- 2022/05/23 00:00 [received]
PHST- 2022/10/07 00:00 [accepted]
PHST- 2022/11/04 06:00 [pubmed]
PHST- 2022/12/24 06:00 [medline]
PHST- 2022/11/03 03:13 [entrez]
AID - 10.1111/jcpt.13798 [doi]
PST - ppublish
SO  - J Clin Pharm Ther. 2022 Dec;47(12):2237-2244. doi: 10.1111/jcpt.13798. Epub 2022 
      Nov 3.